Literature DB >> 11598172

A novel multiparametric approach for analysis of cytoplasmic immunoglobulin light chains by flow cytometry.

C C Chang1, B C Schur, B Kampalath, P Lindholm, C G Becker, D H Vesole.   

Abstract

We describe a novel flow cytometric approach using a two-step acquisition technique to determine the cytoplasmic immunoglobulin light chains (LC) expression. Samples were prepared by a lysed-whole-blood technique and incubated with CD38-PE (phycoerythrin) and CD45-FITC (fluorescein isothiocyanate). The cells were fixed and acquired on an FACSCalibur flow cytometer (first acquisition). The cells were then permeabilized, incubated with either kappa-FITC or lambda-FITC and reacquired (second acquisition). Analysis of the data was performed by gating on the differing intensities of CD38 and evaluating them for the presence of a shifting FITC-positive population from the first acquisition to the second acquisition. The FITC fluorescence intensity of the second acquisition was equal to the sum of surface CD45 expression obtained during the first acquisition and the cytoplasmic LC expression obtained during the second acquisition. Thus, the shifting (increase) of FITC fluorescence intensity during the second acquisition is specifically due to the cytoplasmic expression of either the kappa or lambda LC. We studied 15 multiple myeloma (MM) patients and 10 controls (samples from patients without plasma cell dyscrasias). None of the controls showed evidence of any clonal populations. Thirteen of 15 MM patients exhibited clonal plasma cells (CD38 bright), ranging from 0.01% to 34% of total events collected. In addition, we identified another minute clonal population of lymphocytes (CD38 dim, CD45 bright, low forward and side scatter) in 12 of 13 MM patients with clonal plasma cells. This population, ranging from 0.01% to 0.6% of total events collected, had the same LC restriction as the clonal plasma cells. Patients with a ratio of minor clonal population to clonal plasma cells less than 0.07 tended to remain in partial or complete remission than those with a ratio > or =0.07 (4/5 versus 1/4, P <.1, chi(2)). We conclude that this method is highly sensitive and permits us to identify the minute clonal population of lymphocytes in MM patients. Our preliminary observations with a small cohort of patients imply that this minute clonal population may have important prognostic significance. The prognostic significance should be confirmed by further studies.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11598172     DOI: 10.1038/modpathol.3880427

Source DB:  PubMed          Journal:  Mod Pathol        ISSN: 0893-3952            Impact factor:   7.842


  4 in total

1.  Simplified flow cytometric immunophenotyping panel for multiple myeloma, CD56/CD19/CD138(CD38)/CD45, to differentiate neoplastic myeloma cells from reactive plasma cells.

Authors:  Tae-Dong Jeong; Chan-Jeoung Park; Hyoeun Shim; Seongsoo Jang; Hyun-Sook Chi; Dok Hyun Yoon; Dae-Young Kim; Jung-Hee Lee; Je-Hwan Lee; Cheolwon Suh; Kyoo Hyung Lee
Journal:  Korean J Hematol       Date:  2012-12-24

2.  An approach for diagnosing plasma cell myeloma by three-color flow cytometry based on kappa/lambda ratios of CD38-gated CD138(+) cells.

Authors:  Shoko Nakayama; Taiji Yokote; Yuji Hirata; Kazuki Iwaki; Toshikazu Akioka; Takuji Miyoshi; Ayami Takayama; Uta Nishiwaki; Yuki Masuda; Toshiyuki Ikemoto; Hidema Tanaka; Yasuichiro Nishimura; Motomu Tsuji; Toshiaki Hanafusa
Journal:  Diagn Pathol       Date:  2012-09-28       Impact factor: 2.644

3.  The flow cytometry-defined light chain cytoplasmic immunoglobulin index and an associated 12-gene expression signature are independent prognostic factors in multiple myeloma.

Authors:  X Papanikolaou; D Alapat; A Rosenthal; C Stein; J Epstein; R Owens; S Yaccoby; S Johnson; C Bailey; C Heuck; E Tian; A Joiner; F van Rhee; R Khan; M Zangari; Y Jethava; S Waheed; F Davies; G Morgan; B Barlogie
Journal:  Leukemia       Date:  2015-03-10       Impact factor: 11.528

4.  Targeting the biophysical properties of the myeloma initiating cell niches: a pharmaceutical synergism analysis using multi-scale agent-based modeling.

Authors:  Jing Su; Le Zhang; Wen Zhang; Dong Song Choi; Jianguo Wen; Beini Jiang; Chung-Che Chang; Xiaobo Zhou
Journal:  PLoS One       Date:  2014-01-27       Impact factor: 3.240

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.